Clinical efficacy of anti-programmed death ligand 1 antibody HFC-L1/c4G12 in dogs with malignant tumors: an exploratory study
Journal of Veterinary Medical Science · 2025 · 87 (12) · 1419-1425
DOI: 10.1292/jvms.25-0303 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Veterinary Medical Science, 2025. Verfasst von Satoshi Takagi und 25 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Small Animal Surgery, School of Veterinary Medicine, Azabu University, Kanagawa, Japan. Hauptthemen laut MEDLINE: Dog Diseases, Neoplasms, B7-H1 Antigen, Immune Checkpoint Inhibitors. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Japan Society for the Promotion of Science, Japan Agency for Medical Research and Development.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratory of Small Animal Surgery, School of Veterinary Medicine, Azabu University, Kanagawa, Japan.
- Veterinary Medical Center, Obihiro University of Agriculture and Veterinary Medicine, Hokkaido, Japan.
- Department of Advanced Pharmaceutics, Faculty of Veterinary Medicine, Hokkaido University, Hokkaido, Japan.
- Department of Disease Control, Faculty of Veterinary Medicine, Hokkaido University, Hokkaido, Japan.
- Cancer Research Unit, One Health Research Center, Hokkaido University, Hokkaido, Japan.
- Institute for Vaccine Research and Development (HU-IVReD), Hokkaido University, Hokkaido, Japan.
Förderung
- Japan Society for the Promotion of Science
- Japan Agency for Medical Research and Development
Zitieren
APA
Takagi, S., Tagawa, M., Maekawa, N., Konnai, S., Kagawa, Y., Hosoya, K., Yamauchi, A., Kudo, A., Kamo, S., Kim, S., Kinoshita, R., Deguchi, T., Owaki, R., Tachibana, Y., Yokokawa, M., Takeuchi, H., Nakamura, H., Kato, Y., Kanazawa, S., …, & Ohashi, K. (2025). Clinical efficacy of anti-programmed death ligand 1 antibody HFC-L1/c4G12 in dogs with malignant tumors: an exploratory study. Journal of Veterinary Medical Science, 87(12), 1419-1425. https://doi.org/10.1292/jvms.25-0303
Vancouver
Takagi S, Tagawa M, Maekawa N, Konnai S, Kagawa Y, Hosoya K, et al. Clinical efficacy of anti-programmed death ligand 1 antibody HFC-L1/c4G12 in dogs with malignant tumors: an exploratory study. Journal of Veterinary Medical Science. 2025;87(12):1419-1425. doi:10.1292/jvms.25-0303
BibTeX
@article{Takagi2025,
author = {Takagi, Satoshi and Tagawa, Michihito and Maekawa, Naoya and Konnai, Satoru and Kagawa, Yumiko and Hosoya, Kenji and Yamauchi, Akinori and Kudo, Ayano and Kamo, Shintaro and Kim, Sangho and Kinoshita, Ryohei and Deguchi, Tatsuya and Owaki, Ryo and Tachibana, Yurika and Yokokawa, Madoka and Takeuchi, Hiroto and Nakamura, Hayato and Kato, Yukinari and Kanazawa, Shigeki and Abe, Tomoyuki and Furuta, Takuya and Yamamoto, Keiichi and Suzuki, Yasuhiko and Okagawa, Tomohiro and Murata, Shiro and Ohashi, Kazuhiko},
title = {Clinical efficacy of anti-programmed death ligand 1 antibody HFC-L1/c4G12 in dogs with malignant tumors: an exploratory study},
journal = {Journal of Veterinary Medical Science},
year = {2025},
volume = {87},
number = {12},
pages = {1419--1425},
doi = {10.1292/jvms.25-0303}
}
EUVIMED